Publications by authors named "Daniel Forton"

Claim this Profile
U
Utility and cost-effectiveness of LiverMultiScan for MASLD diagnosis: a real-world multi-national randomised clinical trial.
Elizabeth Shumbayawonda, Marika French, Jane Elizabeth Carolan, Cayden Beyer, Paula Lorgelly, Daniel Forton

Commun Med (Lond)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KIR-HLA interactions extend human CD8+ T cell lifespan in vivo.
Yan Zhang, Ada Wc Yan, Lies Boelen, Linda Hadcocks, Arafa Salam, Daniel Forton

J Clin Invest· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C.
Graham S Cooke, Sarah Pett, Leanne McCabe, Chris Jones, Richard Gilson, Daniel Forton

Wellcome Open Res· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insights from compassionate use of tocilizumab for COVID-19 to inform appropriate design of randomised controlled trials.
Emma H Baker, Kamal Patel, Jonathan Ball, Sarah Edwards, Thomas S Harrison, Daniel M Forton

Br J Clin Pharmacol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First reported case of safe and efficacious use of tocilizumab for treatment of hyperinflammatory syndrome associated with COVID-19 in an allogeneic stem cell transplant patient.
Nicholas Fordham, Emma Baker, Daniel Forton, Matthias Klammer, Kamal Patel

EJHaem· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IgG Seroconversion and Pathophysiology in Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Henry M Staines, Daniela E Kirwan, David J Clark, Emily R Adams, Yolanda Augustin, Daniel Forton

Emerg Infect Dis· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential effect of interferon-alpha treatment on AEA and 2-AG levels.
Zuzanna Zajkowska, Alessandra Borsini, Naghmeh Nikkheslat, Alice Russell, Graziella F Romano, Daniel Forton

Brain Behav Immun· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
Derek C Angus, Lennie Derde, Farah Al-Beidh, Djillali Annane, Yaseen Arabi, Daniel Forton

JAMA· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed.
Kathryn Drysdale, Yevedzo Ntuli, Jonathan Bestwick, William Gelson, Kosh Agarwal, Daniel Forton

Aliment Pharmacol Ther· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expert opinion on managing chronic HCV in patients with neuropsychiatric manifestations.
Daniel Forton, Karin Weissenborn, Mark Bondin, Patrice Cacoub

Antivir Ther· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistent fatigue induced by interferon-alpha: a novel, inflammation-based, proxy model of chronic fatigue syndrome.
Alice Russell, Nilay Hepgul, Naghmeh Nikkheslat, Alessandra Borsini, Zuzanna Zajkowska, Daniel Forton

Psychoneuroendocrinology· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Depression and anxiety in patients receiving interferon-alpha: The role of illness perceptions.
Nilay Hepgul, Carmine M Pariante, Sara Baraldi, Alessandra Borsini, Chiara Bufalino, Daniel M Forton

J Health Psychol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.
Graham R Foster, Kosh Agarwal, Matthew E Cramp, Sulleman Moreea, Stephen Barclay, Daniel M Forton

Hepatology· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
Alberto Zanetto, Sarah Shalaby, Alessandro Vitale, Claudia Mescoli, Alberto Ferrarese, Daniel M Forton

Liver Transpl· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis C virus infection, and neurological and psychiatric disorders - A review.
Lydia Yarlott, Eleanor Heald, Daniel Forton

J Adv Res· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How much of a problem is resistance in treating hepatitis C?
Daniel M Forton

Curr Opin Infect Dis· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis C - the brain strain.
Daniel M Forton

Liver Int· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptomics in Interferon-α-Treated Patients Identifies Inflammation-, Neuroplasticity- and Oxidative Stress-Related Signatures as Predictors and Correlates of Depression.
Nilay Hepgul, Annamaria Cattaneo, Kosh Agarwal, Sara Baraldi, Alessandra Borsini, Daniel M Forton

Neuropsychopharmacology· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.
Graham R Foster, Stephen Pianko, Ashley Brown, Daniel Forton, Ronald G Nahass

Gastroenterology· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extrahepatic morbidity and mortality of chronic hepatitis C.
Francesco Negro, Daniel Forton, Antonio Craxì, Mark S Sulkowski, Jordan J Feld

Gastroenterology· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.
Peter Ferenci, Tarik Asselah, Graham R Foster, Stefan Zeuzem, Christoph Sarrazin, Daniel Forton

J Hepatol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive improvement after HCV eradication: Extending the benefits.
Jasmohan S Bajaj, Daniel M Forton

Hepatology· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement.
Martin Schaefer, Lucile Capuron, Astrid Friebe, Crisanto Diez-Quevedo, Geert Robaeys, Daniel Forton

J Hepatol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis C treatment--clearing the mind.
Daniel M Forton

J Hepatol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis